AGLE logo

Aeglea BioTherapeutics (AGLE) EBITDA

Annual EBITDA

-$83.21 M
-$19.14 M-29.87%

December 31, 2022

Summary

Performance

1-Year Change

-29.87%

3-Year Change

-4.13%

5-Year Change

-203.4%

15-Year Change

-203.4%

AGLE EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

-$8.88 M

3-Year Low

-$83.21 M
AGLE annual EBITDA is currently at its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2022
AGLE previous annual earnings announcement was published on Dec 31, 2022

Next Annual Earnings Report Date

N/A
AGLE next annual earnings announcement has not yet been scheduled

OtherAGLEprofitabilitymetrics:

Annual Revenue

$2.33 M
AGLE annual revenue is $2.33 million

Annual Net Income

-$83.81 M
AGLE annual net profit is -$83.81 million

Annual EBIT

-$84.78 M
AGLE annual earnings before interest & taxes is -$84.78 million

Annual EPS

-$24.75
AGLE annual earnings per share is -$24.75

Quarterly EBITDA

-$33.24 M
-$5.06 M-17.97%

September 30, 2023

Summary

Performance

3-Month Change

-17.97%

1-Year Change

-82.13%

3-Year Change

-86.01%

5-Year Change

-173.23%

AGLE Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

-$856.00 K

3-Year Low

-$33.24 M
AGLE quarterly EBITDA is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2023
AGLE previous earnings announcement was published on Sep 30, 2023

Next Quarterly Earnings Report Date

N/A
AGLE next earnings announcement has not yet been scheduled

OtherAGLEprofitabilitymetrics:

Quarterly Revenue

-
AGLE quarterly revenue value is unknown

Quarterly Net Income

-$40.11 M
AGLE quarterly net profit is -$40.11 million

Quarterly EBIT

-$33.24 M
AGLE quarterly earnings before interest & taxes is -$33.24 million

Quarterly EPS

-$9.34
AGLE quarterly earnings per share is -$9.34

TTM EBITDA

-$98.92 M
-$14.99 M-17.86%

September 30, 2023

Summary

Performance

3-Month Change

-17.86%

1-Year Change

-17.51%

3-Year Change

-23.83%

5-Year Change

-23.77%

AGLE TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

-$856.00 K

3-Year Low

-$98.92 M
AGLE TTM EBITDA is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2023
AGLE previous earnings announcement was published on Sep 30, 2023

Next Quarterly Earnings Report Date

N/A
AGLE next earnings announcement has not yet been scheduled

OtherAGLEprofitabilitymetrics:

TTM Revenue

-
AGLE TTM revenue value is unknown

TTM Net Income

-$294.43 M
AGLE TTM net profit is -$294.43 million

TTM EBIT

-$99.97 M
AGLE TTM earnings before interest & taxes is -$99.97 million

TTM EPS

-$75.67
AGLE TTM earnings per share is -$75.67

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Annual EBITDA

-$83.21 M
AGLE annual EBITDA is -$83.21 million

Annual Net Income

-$83.81 M
AGLE annual net profit is -$83.81 million

Annual Interest Expense

-
AGLE annual interest expense value is unknown

Annual Income Tax

-$136.00 K
AGLE annual income tax is -$136.00 thousand

Annual D&A

$1.57 M
AGLE annual depreciation & amortization is $1.57 million

AGLE EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-29.9%-82.1%-17.5%
3 y3 years-4.1%-86.0%-23.8%
5 y5 years-203.4%-173.2%-23.8%

AGLE EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year+29.9%at low+82.1%at low+54.4%at low
5 y5-year+29.9%at low+427.1%at low+54.4%at low
alltimeall time+836.6%at low+3783.6%at low>+9999.0%at low

Aeglea BioTherapeutics EBITDA History

DateAnnualQuarterlyTTM
Sep 2023
-
-$33.24 M(+18.0%)
-$98.92 M(+17.9%)
Jun 2023
-
-$28.18 M(+53.0%)
-$83.92 M(+8.2%)
Mar 2023
-
-$18.42 M(-3.4%)
-$77.60 M(-6.7%)
Dec 2022
-$83.21 M(+29.9%)
-$19.07 M(+4.5%)
-$83.21 M(-1.1%)
Sep 2022
-
-$18.25 M(-16.5%)
-$84.18 M(-1.9%)
Jun 2022
-
-$21.85 M(-9.1%)
-$85.80 M(+22.1%)
Mar 2022
-
-$24.04 M(+20.0%)
-$70.26 M(+9.7%)
Dec 2021
-$64.07 M(-20.4%)
-$20.03 M(+0.8%)
-$64.07 M(-3.6%)
Sep 2021
-
-$19.88 M(+215.2%)
-$66.45 M(+3.1%)
Jun 2021
-
-$6.31 M(-64.7%)
-$64.44 M(-18.9%)
Mar 2021
-
-$17.85 M(-20.3%)
-$79.47 M(-1.3%)
Dec 2020
-$80.48 M(+0.7%)
-$22.41 M(+25.4%)
-$80.48 M(+0.8%)
Sep 2020
-
-$17.87 M(-16.2%)
-$79.88 M(-5.0%)
Jun 2020
-
-$21.34 M(+13.1%)
-$84.05 M(+3.5%)
Mar 2020
-
-$18.87 M(-13.5%)
-$81.23 M(+1.6%)
Dec 2019
-$79.92 M(+76.9%)
-$21.80 M(-1.1%)
-$79.92 M(+9.0%)
Sep 2019
-
-$22.04 M(+19.0%)
-$73.35 M(+15.6%)
Jun 2019
-
-$18.52 M(+5.5%)
-$63.47 M(+16.4%)
Mar 2019
-
-$17.56 M(+15.3%)
-$54.55 M(+20.8%)
DateAnnualQuarterlyTTM
Dec 2018
-$45.17 M(+64.7%)
-$15.23 M(+25.2%)
-$45.17 M(+23.8%)
Sep 2018
-
-$12.17 M(+26.8%)
-$36.50 M(+13.1%)
Jun 2018
-
-$9.60 M(+17.4%)
-$32.26 M(+10.0%)
Mar 2018
-
-$8.18 M(+24.6%)
-$29.32 M(+6.9%)
Dec 2017
-$27.43 M(+26.0%)
-$6.56 M(-17.3%)
-$27.43 M(+4.0%)
Sep 2017
-
-$7.93 M(+19.1%)
-$26.37 M(+6.7%)
Jun 2017
-
-$6.66 M(+6.0%)
-$24.71 M(+5.1%)
Mar 2017
-
-$6.28 M(+14.0%)
-$23.52 M(+8.0%)
Dec 2016
-$21.77 M(+94.0%)
-$5.51 M(-12.1%)
-$21.77 M(+7.6%)
Sep 2016
-
-$6.27 M(+14.7%)
-$20.23 M(+16.6%)
Jun 2016
-
-$5.46 M(+20.4%)
-$17.36 M(+30.4%)
Mar 2016
-
-$4.54 M(+14.4%)
-$13.31 M(+18.6%)
Dec 2015
-$11.23 M(+26.3%)
-$3.97 M(+17.0%)
-$11.23 M(+7.7%)
Sep 2015
-
-$3.39 M(+139.9%)
-$10.43 M(+2.5%)
Jun 2015
-
-$1.41 M(-42.3%)
-$10.17 M(-3.0%)
Mar 2015
-
-$2.45 M(-22.6%)
-$10.48 M(+18.0%)
Dec 2014
-$8.88 M
-$3.17 M(+1.1%)
-$8.88 M(+55.4%)
Sep 2014
-
-$3.13 M(+81.7%)
-$5.72 M(+121.5%)
Jun 2014
-
-$1.73 M(+101.5%)
-$2.58 M(+201.5%)
Mar 2014
-
-$856.00 K
-$856.00 K

FAQ

  • What is Aeglea BioTherapeutics annual EBITDA?
  • What is the all time high annual EBITDA for Aeglea BioTherapeutics?
  • What is Aeglea BioTherapeutics annual EBITDA year-on-year change?
  • What is Aeglea BioTherapeutics quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Aeglea BioTherapeutics?
  • What is Aeglea BioTherapeutics quarterly EBITDA year-on-year change?
  • What is Aeglea BioTherapeutics TTM EBITDA?
  • What is the all time high TTM EBITDA for Aeglea BioTherapeutics?
  • What is Aeglea BioTherapeutics TTM EBITDA year-on-year change?

What is Aeglea BioTherapeutics annual EBITDA?

The current annual EBITDA of AGLE is -$83.21 M

What is the all time high annual EBITDA for Aeglea BioTherapeutics?

Aeglea BioTherapeutics all-time high annual EBITDA is -$8.88 M

What is Aeglea BioTherapeutics annual EBITDA year-on-year change?

Over the past year, AGLE annual EBITDA has changed by -$19.14 M (-29.87%)

What is Aeglea BioTherapeutics quarterly EBITDA?

The current quarterly EBITDA of AGLE is -$33.24 M

What is the all time high quarterly EBITDA for Aeglea BioTherapeutics?

Aeglea BioTherapeutics all-time high quarterly EBITDA is -$856.00 K

What is Aeglea BioTherapeutics quarterly EBITDA year-on-year change?

Over the past year, AGLE quarterly EBITDA has changed by -$14.99 M (-82.13%)

What is Aeglea BioTherapeutics TTM EBITDA?

The current TTM EBITDA of AGLE is -$98.92 M

What is the all time high TTM EBITDA for Aeglea BioTherapeutics?

Aeglea BioTherapeutics all-time high TTM EBITDA is -$856.00 K

What is Aeglea BioTherapeutics TTM EBITDA year-on-year change?

Over the past year, AGLE TTM EBITDA has changed by -$14.74 M (-17.51%)